X4 Pharmaceuticals, Inc — Director's Dealing 2022

Nov 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2022-11-03

Reporting Person: Baldry Mark (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-03	Stock Option (right to buy)	$1.89	A	341000	Acquired	2032-11-03	Common Stock (341000.0)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.